SGLT2i与DPP-4i作为附加治疗与PAD相关手术事件(截肢、支架置入或血管手术)风险:退伍军人糖尿病队列研究
该回顾性队列研究纳入美国退伍军人糖尿病患者,比较SGLT2i与DPP-4i作为二甲双胍、磺脲类或胰岛素附加治疗时PAD手术结局风险。倾向评分加权后SGLT2i组76,072例 vs DPP-4i组75,833例使用事件,SGLT2i组PAD事件率11.2/1000人年 vs DPP-4i组10.0/1000人年,aHR 1.18(95%CI 1.08-1.29)。结论:SGLT2i作为附加治疗与PAD手术风险升高相关。
要点
- SGLT2i组PAD事件率11.2/1000人年 vs DPP-4i组10.0/1000人年,aHR 1.18(95%CI 1.08-1.29)。
- 停药后允许360天事件时,aHR为1.16(95%CI 1.06-1.26)。
- 研究为回顾性队列,比较SGLT2i与DPP-4i作为附加治疗的PAD手术复合结局风险。
核心结论
- SGLT2i作为附加降糖治疗与DPP-4i相比,PAD手术的病因特异性风险升高相关。
研究设计与样本
- 回顾性队列研究,纳入2000年10月1日至2021年12月31日期间接受退伍军人健康管理局诊疗的≥18岁美国退伍军人糖尿病患者,数据链接Medicare、Medicaid和国家死亡索引。
- 评估SGLT2i或DPP-4i作为二甲双胍、磺脲类或胰岛素单药或联合治疗的附加用药,与PAD手术操作(外周血运重建和截肢)的关联。
- 采用Cox比例风险模型进行至PAD事件时间分析,在倾向评分加权队列中比较SGLT2i与DPP-4i的PAD事件风险,考虑死亡竞争风险,并允许停药后90天或360天内发生事件。
- 加权队列包括SGLT2i组76,072例 vs DPP-4i组75,833例使用事件;中位年龄69岁,HbA1c 8.4%(IQR 7.5-9.4%),中位糖尿病病程10.1年(IQR 6.6-14.6)。
主要发现
- SGLT2i组发生874例PAD事件,DPP-4i组发生780例PAD事件。
- SGLT2i组事件率为11.2(95%CI 10.5-11.9)/1000人年 vs DPP-4i组10.0(95%CI 9.4-10.6)/1000人年,aHR 1.18(95%CI 1.08-1.29)。
- 当允许SGLT2i停药后360天内发生PAD事件时,aHR为1.16(95%CI 1.06-1.26)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the risk of composite peripheral artery disease (PAD) surgical outcome, including peripheral revascularization and amputation procedures, between new users of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP-4is). RESEARCH DESIGN AND METHODS: This retrospective cohort study of U.S. veterans age ≥18 years with diabetes who received care from the Veterans Health Administration was performed from 1 October 2000 to 31 December 2021. Data were linked to Medicare, Medicaid, and the National Death Index. New use of SGLT2i or DPP-4i medications as an add-on to metformin, sulfonylurea, or insulin treatment alone or in combination was evaluated for an association with PAD surgical procedure for peripheral revascularization and amputation. A Cox proportional hazards model for time-to-PAD event analysis compared the risk of a PAD event between SGLT2is and DPP-4is in a propensity score-weighted cohort with a competing risk of death and allowance for events to occur up to 90 days or 360 days after stopping SGLT2is. RESULTS: The weighted cohort included 76,072 SGLT2i vs. 75,833 DPP-4i use episodes. The median age was 69 years, HbA1c was 8.4% (interquartile range [IQR] 7.5-9.4%), and the median diabetes duration was 10.1 (IQR 6.6-14.6) years. There were 874 and 780 PAD events among SGLT2i and DPP-4i users, respectively, for an event rate of 11.2 (95% CI 10.5-11.9) and 10.0 (9.4-10.6) per 1,000 person-years (adjusted hazard ratio [aHR] 1.18 [95% CI 1.08-1.29]). When PAD events were allowed for 360 days after SGLT2i use ended, the aHR was 1.16 (95% CI 1.06-1.26). CONCLUSIONS: SGLT2i as an add-on diabetes therapy was associated with an increased cause-specific hazard of PAD surgeries compared with DPP-4i.
引用
- Griffin KE, Snyder K, Javid AH, et al. Use of SGLT2i Versus DPP-4i as an Add-on Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes. Diabetes Care. 2025. PMID: 39977627. doi:10.2337/dc24-1546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。